Considerable Gaps Seen in Provision of Effective Treatment for Opioid Addiction
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, July 16, 2024 -- There are considerable gaps in provision of effective treatments for opioid use disorders (OUD) at U.S. substance use disorder (SUD) treatment facilities, according to a study published online July 11 in the Journal of the American Medical Association.
Tae Woo Park, M.D., from the University of Pittsburgh, and colleagues conducted a cross-sectional study of specialty outpatient SUD treatment facilities that treat OUD. The prevalence of available treatments individually and combined was reported. Treatments offered in federally certified opioid treatment program (OTP) and non-OTP facilities were compared.
Overall, 17,353 representatives from SUD facilities were surveyed. OUD treatment was offered at 12,060 outpatient facilities: 1,925 and 10,135 OTPs and non-OTPs, respectively. The researchers found that 99.4 and 55.1 percent of OTP and non-OTP facilities offered medications for OUD (MOUD), respectively, and 35.2 percent of facilities offered psychosocial treatments only. Of the facilities that offered MOUD, a higher proportion of OTPs versus non-OTPs offered any MOUD plus contingency management (53.3 versus 41.6 percent), and a lower proportion of OTPs offered any MOUD, any psychosocial treatment, other SUD treatment, and mental health services (16.7 versus 33.5 percent). Overall, 62.2, 45.6, and 2.0 percent of facilities offered at least one, at least two, and all four MOUD types, respectively. A lower proportion of non-OTPs offered sublingual and injectable buprenorphine compared with OTPs (49.7 versus 83.4 percent; 22.4 versus 26.4 percent); injectable naltrexone was offered at similar rates. OTPs offered contingency management more frequently than non-OTPs (54.1 versus 40.2 percent).
"Substance use treatment facilities reported significant gaps in provision of effective treatments for OUD," the authors write.
One author reported ties to relevant organizations.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-07-17 01:15
Read more
- Report Finds Big Disparities in Americans' Well-Being by Region
- Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the US for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
- Ordinal Score Predicts Freedom From Epilepsy One Year After Surgery
- Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
- FDA Approves Kebilidi (eladocagene exuparvovec-tneq) Gene Therapy for the Treatment of AADC Deficiency
- Florida Fails to Pass Amendment Legalizing Recreational Weed
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions